This is the leading international conference in lysophospholipid biology, attracting participants from all continents. This SRC will focus on the physiological and pathophysiological roles of sphingosine 1-phosphate, lysophosphatidic acid and other lysophospholipids. New and established basic scientists, clinical researchers, academics and industry partners are brought together to share expertise and foster collaboration, thereby accelerating the pace of scientific discovery and facilitating translation from early research to clinical practice. Indeed, the development of Fingolimod, the first oral treatment for multiple sclerosis, is an excellent example of this, as first reported at this conference in 2001.
The conference provides opportunities for substantive interactions between early-stage and established basic, translational and pharmaceutical investigators with an interest in lysophospholipid biology in health and disease. Presentations and posters (with several prizes) will range from molecular aspects of lysophospholipid biology through to emerging therapeutics, genetic and disease models and molecular modelling. Late-breaking scientific advances and junior investigators will feature on the final program, which includes keynote lectures, the Journal of Lipid Research Lectureship and a careers workshop for early career scientists.